Data on Scribe’s X-Editor technologies validates the high activity, specificity and deliverability achievable through CRISPR by Design™

Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design™ approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, Calif. and virtually from May 16-20, 2023.

Scribe’s suite of XE genome editing tools are comprehensively engineered from natural CRISPR-Cas enzymes to exhibit increased activity, specificity and deliverability. The company’s presentation will include data demonstrating the potential of the company’s platform and CRISPR by Design™ approach to overcome challenges with efficacy and safety that existing technologies face.

Oral Presentation Title: Comprehensive Engineering of CasX Holoenzyme to Create an X-Editor with High Activity, Specificity and Deliverability

Abstract Number: 262

Session Title: Genome & Epigenome Editing Technologies I

Date: Friday, May 19, 2023

Time: 5:15 - 5:30 p.m. PT

Location: Concourse Hall 152 & 153, Los Angeles Convention Center, Los Angeles, CA

Speaker: Addison Wright, Ph.D., Principal Scientist at Scribe

About Scribe Therapeutics

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe engineers bacterial immune systems into genetic medicines through its CRISPR by Design™ approach leveraging all previous iterations of CRISPR technology. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribe’s mission to engineer the future of genetic medicine, visit www.scribetx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502006186/en/